➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Dow
Baxter
Merck
Boehringer Ingelheim

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Aclidinium Bromide; Formoterol Fumarate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00706914 Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Completed AstraZeneca Phase 2 2008-06-01 This exploratory study will compare the efficacy of the fixed-dose combination (FDC) of aclidinium bromide and formoterol fumarate once daily in the morning and placebo once in the evening vs. the FDC once daily in the morning and formoterol fumarate once in the evening vs. formoterol fumarate twice daily. The study will assess pulmonary function and symptoms in patients with moderate to severe COPD.
NCT01049360 Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo Completed AstraZeneca Phase 2 2009-12-01 The purpose of this study is to evaluate the efficacy of this multicenter, randomized, double-blind, placebo-controlled, 4-period, incomplete-block crossover, dose-ranging study comparing 2 fixed dose combinations (FDCs) of aclidinium bromide with formoterol fumarate or with placebo, aclidinium bromide and formoterol fumarate, all administered twice a day (BID) in patients with stable, moderate to severe chronic obstructive pulmonary disease (COPD) beginning with a 2-week run-in period and with a 7-10 day washout each between treatment period.
NCT01078623 Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate Completed AstraZeneca Phase 2 2010-02-01 The purpose of this multicenter, dose-ranging study is to compare two Fixed-Dose Combinations of aclidinium bromide and formoterol fumarate with placebo, aclidinium bromide and formoterol fumarate, all administered BID in patients with stable, moderate to severe COPD. Every treatment period is 14-days long and there is a 7-days wash-out period in between them. The trial starts with a run in phase of 10 to 17-days duration and it ends up with a follow up contact 14-days after last treatment dose.
NCT01437397 Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Completed AstraZeneca Phase 3 2011-09-01 The purpose of this Phase III study is to assess the maintenance bronchodilator effects of the fixed dose combination versus monotherapies. This study will also assess the effects of the fixed dose combination in terms of COPD symptoms, disease related health status and the long-term safety and tolerability of the fixed dose combination. This study will include a 24 week treatment period, preceding by a run-in period, followed by a two week follow up visit. All patients will be randomized to one of four treatment arms or placebo.
NCT01437540 Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Completed AstraZeneca Phase 3 2011-09-01 The purpose of this study is to assess the long-term safety and tolerability of inhaled aclidinium bromide/formoterol in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD).
NCT01462942 Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination Completed AstraZeneca Phase 3 2011-10-01 The objective is to provide data supporting the use of LAS40464 as an efficacious and safe maintenance bronchodilator treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Aclidinium Bromide; Formoterol Fumarate

Condition Name

Condition Name for Aclidinium Bromide; Formoterol Fumarate
Intervention Trials
Chronic Obstructive Pulmonary Disease 7
Pulmonary Disease, Chronic Obstructive 3
Chronic Obstructive Pulmonary Disease (COPD) 3
Smoking 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Aclidinium Bromide; Formoterol Fumarate
Intervention Trials
Pulmonary Disease, Chronic Obstructive 14
Lung Diseases, Obstructive 13
Lung Diseases 13
Chronic Disease 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Aclidinium Bromide; Formoterol Fumarate

Trials by Country

Trials by Country for Aclidinium Bromide; Formoterol Fumarate
Location Trials
United States 181
Canada 21
Australia 9
Hungary 4
Czech Republic 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Aclidinium Bromide; Formoterol Fumarate
Location Trials
Florida 7
Oregon 7
North Carolina 7
Arizona 7
South Carolina 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Aclidinium Bromide; Formoterol Fumarate

Clinical Trial Phase

Clinical Trial Phase for Aclidinium Bromide; Formoterol Fumarate
Clinical Trial Phase Trials
Phase 4 3
Phase 3 8
Phase 2 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Aclidinium Bromide; Formoterol Fumarate
Clinical Trial Phase Trials
Completed 10
Not yet recruiting 3
Recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Aclidinium Bromide; Formoterol Fumarate

Sponsor Name

Sponsor Name for Aclidinium Bromide; Formoterol Fumarate
Sponsor Trials
AstraZeneca 15
Parexel 2
Menarini Group 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Aclidinium Bromide; Formoterol Fumarate
Sponsor Trials
Industry 18
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Boehringer Ingelheim
Express Scripts
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.